A mechanistic model of in vitro plasma activation to evaluate therapeutic kallikrein-kinin system inhibitors
Fig 3
FXII activation versus DXS concentration via two alternative FXII activation mechanisms.
Comparison of the Røjkjær and Schousboe [44] experimental data with simulations using optimised kinetic parameters for FXII activation, via either a combination of FXII autoactivation (reaction 3) and FXII self-activation (reaction 4), or just FXII self-activation in the presence of background αFXIIa.